Book an appointment with us, or search the directory to find the right lawyer for you directly through the app.
Find out more
Managing Risk in a Changing Regulatory Environment
The latest Transport & Insurance edition of Law Update examines key legal and regulatory developments affecting businesses, insurers and logistics providers across the region.
From liability for damaged goods and freight forwarding arrangements to the UAE’s new Takaful Insurance Regulation, our lawyers explore the practical implications for managing risk, protecting commercial interests and identifying new opportunities.
The Saudi Food and Drug Authority (“SFDA”) issued its General Guideline on Regulatory and Scientific Requirements for Development and Approval of Biosimilars (Version 1.0), effective 10 July 2026 (“Biosimilars Approval Guideline”). This guideline provide clarification on SFDA’s current regulatory regime on biosimilarity principles, articulates an updated framework for clinical evidence requirements, and offers a pathway for a tailored approach to comparative efficacy studies.
This Biosimilars Approval Guideline remains consistent with the Saudi National Biotechnology Strategy and the goal of localizing biosimilar manufacturing in KSA. It does not replace the existing guidance documents regarding biosimilars; rather, it enhances them.
Now, we dive into the key components of this guidelines.
Biosimilar applicants must submit in marketing authorization application (“MAA”) dossier the complete standalone Quality/Chemistry, Manufacturing, and Controls (CMC) data (Electronic Common Technical Document (eCTD) Quality Overall Summary of Module 2 and Module 3). This is supplemented by biosimilar comparability exercises at the quality, non-clinical, and clinical levels, where required to demonstrate the biosimilarity against the RP (as per the applicable SFDA guidelines, including this Biosimilars Approval Guideline)
The foundational requirements in the Biosimilars Approval Guideline are:
Biosimilarity Protocol:
A robust, pre-defined protocol covering reference product (“RP”) selection, comparative quality exercise (“CQE”) batch requirements (at least 15 RP batches and at least 10 biosimilar batches from the intended commercial process, although the amount may be adjusted for biosimilars of orphan medicines), risk assessment per ICH Q9(R1), statistical approaches, and a plan for handling quality differences. A justification letter must be included if requesting the waiver of certain comparative clinical studies, in accordance with the conditions specified in this Biosimilars Approval Guideline.
Details for the required content of the biosimilar comparability exercise are provided in the other relevant SFDA guidelines for biosimilars. Yet, companies developing biosimilars should seek scientific advice from SFDA for further reassurance on the adequacy of their development program. This can be specifically valuable in cases where the available guidelines may not address a particular situation, or a developer would like to deviate from the guidance for certain justifiable reasons, and when a tailored biosimilar approach with waiving of the comparative efficacy studies (“CES”) in patients is pursued.
Reference Product Selection:
The selection of the reference product should meet the SFDA requirements as defined in the SFDA Guidelines on Quality Considerations for Development and Comparability Assessment of Biosimilars, as well as this new Biosimilars Approval Guideline. The RP must be an originator product approved by SFDA or a stringent regulatory authority (“SRA”) with expired patent and data exclusivity, a well-established safety/efficacy profile, and must not be another biosimilar.
Tailored Comparative Efficacy Studies Approach:
Notably, SFDA now permits waiver of CES in patients on a case-by-case basis. An internal SFDA analysis found no cases where a product demonstrated positive CQE outcomes but negative outcome in the comparative clinical trial, reinforcing the position that robust quality-level biosimilarity at the quality level is predictive of comparable clinical performance. CES remain required where the RP’s mechanism of action is poorly understood, the molecule cannot be sufficiently characterized, differences in critical quality attributes between the RP and proposed biosimilar cannot be scientifically justified, or safety/immunogenicity cannot be adequately assessed from PK trials alone.
Quality and Comparability Considerations:
Details of the quality considerations relevant for the development and comparability assessment of biosimilars are discussed in the SFDA Guidelines on Quality Considerations for Development and Comparability Assessment of Biosimilars. In this new Biosimilars Approval Guideline, in terms of CQE, the SFDA details that the same scientific principles apply as those given in the ICH Q5E guideline for evaluation of the impact of changes in the manufacturing process of a biological medicinal product. Specifically, the SFDA requires that the dossier for MAA must contain a well-designed and acceptable biosimilarity protocol for comparability exercises along with the results of the CQE comparing structural and functional attributes (using in vitro assays) between the proposed biosimilar and the RP.
SFDA acknowledges that comparative in vivo studies are of limited use in the regulatory assessment of biosimilars; thus, comparative non-clinical PK/PD and/or toxicological studies may only be required in exceptional cases.
Interchangeability and Extrapolation:
This Biosimilars Approval Guideline confirms that SFDA-approved biosimilars are considered interchangeable with their RPs; no additional systematic switching studies are required post-authorization. Extrapolation to additional RP indications is permitted with proper scientific justification regarding mechanism of action and in compliance with the SFDA policy on patent for pharmaceutical products.
Waiver of Requirements
Applicants may request a waiver of unnecessary comparative clinical studies; these requests will be evaluated by SFDA on case-by-case basis and must meet the requirements set out in this Biosimilars Approval Guideline.
This update continues to reflect SFDA’s commitment to facilitating availability of, affordability of, and broad patient access to biosimilars. The streamlined clinical requirements, interchangeability position, and extrapolation framework are designed to accelerate market entry without compromising safety standards.
In addition to these regulatory requirements in respect of the product, the following are the key considerations that we see during our work with life sciences business (originators/brand name, biosimilars, generics, biologics, combination drugs, etc.):
To learn more about our services and get the latest legal insights from across the Middle East and North Africa region, click on the link below.